Biogen Advances Alzheimer's Drug Despite Disappointing Trial Data

Biogen announced its decision to move an experimental Alzheimer's drug into a late-stage trial, despite the drug missing its primary endpoint in mid-stage clinical trials. The company is proceeding with the drug's development despite the initial disappointing data.